The purpose of this randomized, double blinded, placebo controlled study is to assess the
efficacy and safety of tofacitinib in hospitalized adult (18-99 years old) patients with
SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of
inflammation but do not need mechanical ventilation.